Surveillance of Humira in Korean JIA Patients

Completed

Brief Summary: Approximately 600 pediatric patients prescribed Humira Injection in usual practice according to the approved Korean product label will be registered into this observational study. Baseline data will be obtained at enrollment including demographics, underlying diseases and complications especially in regard to purified protein derivative (PPD) skin test, and chest X-ray. At routine visits for Humira Injection administration, which will occur according to usual medical practice, concomitant medication information and adverse events information will be collected for up to 70 days after the last administration of Humira.

Recruitment & Eligibility

Inclusion Criteria

Patients from 2 years of age who were diagnosed with polyarticular juvenile idiopathic arthritis (JIA) or patients from 6 years of age who were diagnosed with enthesitis-related arthritis (ERA).
Polyarticular juvenile idiopathic arthritis (JIA) patients for whom the response to previous disease-modifying anti rheumatic drug therapy has been inadequate
Patients who give written authorization form to use their personal and health data from legal parents or representative.
Physician will refer to the product market authorization (label) for inclusion criteria.

Exclusion Criteria

Patients with known hypersensitivity to Humira or any of its excipients.
Patients who is participating on other clinical trials.
Physician will refer to the product market authorization (label) for exclusion criteria.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events	Adverse Events (AEs) were collected from informed consent to within 70 days following the last scheduled administration of Humira (up to 22 weeks)	An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either related, possible, probably not, not related, or unassessable. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above.

Secondary Outcome Measures

Name	Time	Method
Changes in Active Joint Count From Baseline and 12 Weeks Post-Treatment	From the first administration (Day 1) to approximately 12 weeks (±4 weeks)	Active Joint Count will be assessed and collected by participating investigators in routine medical practice. Sixty-eight joints were assessed by physical examination. Active joints are defined as joints with positive results for tenderness, swelling, pain on passive motion, or limitation of passive motion. Higher scores represent higher disease activity.
Physician's Global Assessment of the Disease	From the first administration (Day 1) to approximately 12 weeks (±4 weeks)	The Physician's global assessment of the disease assessment was evaluated as 'Improved,' 'Not changed,' 'Aggravated,' or 'Not assessable.'
Parent's Global Assessment for Effectiveness	From the first administration (Day 1) to approximately 12 weeks (±4 weeks)	Parent's global assessment for effectiveness was evaluated as 'Improved,' 'Not changed,' 'Aggravated,' or 'Not assessable.'

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial